{"id":5874,"date":"2021-10-15T16:16:21","date_gmt":"2021-10-15T15:16:21","guid":{"rendered":"https:\/\/www.ab-science.com\/pipeline\/masitinib-apercu\/syndrome-dactivation-des-mastocytes\/"},"modified":"2025-05-21T14:12:07","modified_gmt":"2025-05-21T13:12:07","slug":"syndrome-d-activation-des-mastocytes","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/","title":{"rendered":"Syndrome d\\’Activation des Mastocytes"},"content":{"rendered":"

[vc_row][vc_column]

<\/span>\u00c0 propos du syndrome d'activation des mastocytes<\/span><\/div><\/div>
<\/div>[vc_column_text]Le syndrome d’activation des mastocytes (MCAS) est une maladie caus\u00e9e par une activation anormale des mastocytes, qui peut entra\u00eener des sympt\u00f4mes li\u00e9s \u00e0 la lib\u00e9ration de m\u00e9diateurs mastocytaires d’une gravit\u00e9 allant de l\u00e9g\u00e8re \u00e0 mena\u00e7ant le pronostic vital.\u00a0 Ainsi, le MCAS est similaire \u00e0 la mastocytose syst\u00e9mique indolente et peu \u00e9volutive (ISM\/SSM), mais il existe des diff\u00e9rences importantes qui font du MCAS une maladie distincte de la mastocytose syst\u00e9mique. Dans le cas de la mastocytose, des mutations bien d\u00e9finies entra\u00eenent une population anormale de mastocytes avec une augmentation marqu\u00e9e de la prolif\u00e9ration dans les tissus, alors que le syndrome MCAS est d\u00fb \u00e0 une plus grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 mutationnelle (mal d\u00e9finie) qui est associ\u00e9e \u00e0 une activation aberrante des mastocytes, malgr\u00e9 une augmentation modeste de leur nombre en raison d’une apoptose r\u00e9duite.[\/vc_column_text]
<\/span>Positionnement du masitinib dans le syndrome d'activation des mastocytes<\/span><\/div><\/div>
<\/div>[vc_column_text]Le masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Dans la mesure o\u00f9 le masitinib a \u00e9t\u00e9 con\u00e7u pour \u00eatre un puissant inhibiteur de l’activation des mastocytes (gr\u00e2ce \u00e0 son action contre les tyrosines kinases de type sauvage c-Kit, Lyn et Fyn), il est particuli\u00e8rement bien adapt\u00e9 au traitement du MCAS s\u00e9v\u00e8re, contrairement aux autres inhibiteurs de la tyrosine kinase c-kit qui ciblent g\u00e9n\u00e9ralement des mutations sp\u00e9cifiques de c-Kit associ\u00e9es \u00e0 la mastocytose syst\u00e9mique. Il n’existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re ou de m\u00e9dicament en d\u00e9veloppement clinique dans cette indication.[\/vc_column_text]
<\/div>
<\/span>\u00c9tude de phase 2 en cours avec le masitinib dans le syndrome d'activation des mastocytes<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a re\u00e7u l\u2019autorisation d\u2019initier une \u00e9tude de phase 2 chez les patients atteints du syndrome d’activation des mastocytes s\u00e9v\u00e8re.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text]Le syndrome d’activation des mastocytes (MCAS) est une maladie caus\u00e9e par une activation anormale des mastocytes, qui peut entra\u00eener des sympt\u00f4mes li\u00e9s \u00e0 la lib\u00e9ration de m\u00e9diateurs mastocytaires d’une gravit\u00e9 allant de l\u00e9g\u00e8re \u00e0 mena\u00e7ant le pronostic vital.\u00a0 Ainsi, le MCAS est similaire \u00e0 la mastocytose syst\u00e9mique indolente et peu \u00e9volutive (ISM\/SSM), mais il existe…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3763,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5874","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nSyndrome d\\'Activation des Mastocytes<\/title>\n<meta name=\"description\" content=\"Masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Il n'existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndrome d\\'Activation des Mastocytes\" \/>\n<meta property=\"og:description\" content=\"Masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Il n'existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T13:12:07+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/syndrome-d-activation-des-mastocytes\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/syndrome-d-activation-des-mastocytes\\\/\",\"name\":\"Syndrome d\\\\'Activation des Mastocytes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-10-15T15:16:21+00:00\",\"dateModified\":\"2025-05-21T13:12:07+00:00\",\"description\":\"Masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Il n'existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/syndrome-d-activation-des-mastocytes\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/syndrome-d-activation-des-mastocytes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/syndrome-d-activation-des-mastocytes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-overview\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Syndrome d\\\\’Activation des Mastocytes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Syndrome d\\'Activation des Mastocytes","description":"Masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Il n'existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/","og_locale":"fr_FR","og_type":"article","og_title":"Syndrome d\\'Activation des Mastocytes","og_description":"Masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Il n'existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re.","og_url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/","og_site_name":"AB Science","article_modified_time":"2025-05-21T13:12:07+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/","url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/","name":"Syndrome d\\'Activation des Mastocytes","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2021-10-15T15:16:21+00:00","dateModified":"2025-05-21T13:12:07+00:00","description":"Masitinib est d\u00e9velopp\u00e9 dans les formes s\u00e9v\u00e8res du MCAS. Il n'existe actuellement aucun traitement approuv\u00e9 pour le MCAS s\u00e9v\u00e8re.","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/syndrome-d-activation-des-mastocytes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Masitinib","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-overview\/"},{"@type":"ListItem","position":4,"name":"Syndrome d\\’Activation des Mastocytes"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/5874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=5874"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/5874\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3763"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=5874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}